From: Long-acting olanzapine versus long-acting risperidone for schizophrenia in Spain – a cost-effectiveness comparison
Adverse events a
OLAI
RLAI
Weight gain
9.0
6.0
Extra-pyramidal symptoms
15.0
25.0
Tardive dyskinesia
0.0
Somnolence
7.0
5.0
Sexual dysfunction
3.0
Post-injection syndrome
2.0
Suicide